60284-98-2

Upstream product

• 111627-25-9 α,α-bis-(4-fluorophenyl)-1-(phenylmethyl)-4-piperidinemethanol 
• 24228-40-8 N-benzyl isonipecotic acid ethyl ester 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 96835-28-8 α,α-bis(4-fluorophenyl)-4-pyridinemethanol 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 111627-01-1 1-[4-[3-[4-[Bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]-2-methoxyphenyl]ethanone hydrochloride 
• 117023-93-5 1-<4-<3-<4--1-piperidinyl>-2-hydroxypropoxy>-2-hydroxy-3-propylphenyl>ethanone hydrochloride 
• 60284-71-1 AHR 5333 
• 111626-03-0 1-[3-(4-chlorophenoxy)propyl]-α,α-bis(4-fluorophenyl)-4-piperidinemethanol 
• 117023-60-6 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]phenyl]-1-propanone 
• 111626-33-6 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]-phenyl]ethanone 
• 111626-52-9 1-[3-[4-(1,1-dimethylethyl)phenoxy]propyl]-α,α-bis(4-fluorophenyl)-4-piperidinemethanol 
• 111625-85-5 α,α-Bis(4-fluorophenyl)-1-(3-phenoxypropyl)-4-piperidinemethanol oxalate 
• 117023-08-2 Bis-(4-fluoro-phenyl)-[1-(3-phenylsulfanyl-propyl)-piperidin-4-yl]-methanol; compound with oxalic acid 
• 117023-53-7 1-[3-(4-Ethylphenoxy)propyl]-α,α-bis(4-fluorophenyl)-4-piperidinemethanol oxalate 
• 117023-55-9 Bis-(4-fluoro-phenyl)-{1-[3-(4-isopropyl-phenoxy)-propyl]-piperidin-4-yl}-methanol; compound with oxalic acid 
• 117039-51-7 1-[3-(3-{4-[Bis-(4-fluoro-phenyl)-hydroxy-methyl]-piperidin-1-yl}-propoxy)-phenyl]-ethanone; compound with oxalic acid 
• 117023-59-3 Bis-(4-fluoro-phenyl)-{1-[3-(4-methanesulfinyl-phenoxy)-propyl]-piperidin-4-yl}-methanol; compound with oxalic acid 
• 117023-62-8 1-[4-(3-{4-[Bis-(4-fluoro-phenyl)-hydroxy-methyl]-piperidin-1-yl}-propoxy)-phenyl]-2-methyl-propan-1-one; compound with oxalic acid 

Relevant academic research and scientific papers

OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS

The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Benzopyranones, a method for producing them and uses therefor

Novel 2H-1-benzopyran-2-ones (coumarin derivatives) of the general formula (I) are provided: STR1 wherein R1, R2, R3, R4, X and Y are defined as in the specification, and the addition compounds thereof with physiologically compatible acids, intermediates and methods for the preparation thereof. The coumarin compounds possess a neuroprotective and anti-allergic action.

Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents

A method of treating cardiac dysfunction, the effects of histamine, and gastric secretion excesses with aryl(alkyl and alkylene)-N-[(phenoxy and phenythio)alkyl]aminoheterocyclics corresponding to the formula: STR1 wherein Ar is phenyl or substituted phenyl; R is phenyl, substituted phenyl, pyridinyl or cycloalkyl; A is hydrogen, hydroxy, cyano, amido and amino; Q is --CH2 --, --CH--, or --CHOH--; d and n are zero or one and the dotted lines form double bonds consistent with the valence of carbon; p is zero, one or two; m is one to six inclusive; B is oxygen, nitrogen, sulfur, sulfinyl or sulfonyl; z is zero or one; l is zero or one; W is hydrogen, loweralkyl, halo, nitro, loweralkoxy or hydroxy; X is hydrogen, loweralkyl, halogen, loweralkoxy or hydroxy; Y is --CH(OH)CH2 OH, --CH(OH)C(O)OH, --C(O)C(O)OH, --C(O)CH2 OH,--C(O)C(O)OCH3, --C(O)C(O)OC2 H5, --CH2 C(O)OC2 H5, --CH(OH)C(O)OCH3, --CH(OH)C(O)OC2 H5 or --C(O)CH2 OC(O)CH3 ; and the pharmaceutically acceptable salts thereof; in addition to the above methods of treatment, compounds wherein (B)z is oxygen are useful in a method of treating Gell and Coombs type 1 allergic responses in mammals.

Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment

A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: STR1 wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH2 -- or STR2 n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the α carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.

Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-piperidines and Structurally Related Compounds

A series of 4-(diarylhydroxymethyl)-1-piperidines was synthesized and evaluated for antiallergy activity.Several analogues had potent activity in the passive foot anaphylaxis (PFA) assay, an IgE-mediated model useful in the detection of compounds possessing antiallergic activity.In particular 1--1-piperidinyl>propoxy>-3-methoxyphenyl>ethanone (1, AHR-5333) was more potent than oxatomide and terfenadine in this assay.

4-[(α,α-diaryl)-hydroxymethyl]-1-piperidinylalkyl-cyclic carbamate derivatives as allergic response inhibitors

4-[(α,α-Diaryl)-hydroxymethyl]-1-piperidinylalkylcyclic carbamate derivatives having the formula: STR1 wherein; R is hydrogen, loweralkyl, cycloalkyl, phenyl and substituted phenyl; Ar and Ar1 are phenyl, substituted phenyl or pyridinyl; alk is a straight or branched hydrocarbon chain; R1 is loweralkyl substituted for hydrogen on a ring carbon. The compounds are useful antihistamines and in controlling allergic response.